LOGIN  |  REGISTER
Assertio

Travere Therapeutics to Participate at Upcoming Investor Conferences

November 04, 2025 | Last Trade: US$39.64 0.64 -1.59

SAN DIEGO / Nov 04, 2025 / Business Wire / Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:

Guggenheim's 2nd Annual Healthcare Innovation Conference
Presenting on Tuesday, November 11, 2025, at 9:00 a.m. ET

Stifel 2025 Healthcare Conference
Wednesday, November 12, 2025

TD Cowen Immunology & Inflammation Summit
Presenting on Thursday, November 13, 2025, at 4:00 p.m. ET

Jefferies Global Healthcare Conference
Presenting on Tuesday, November 18, 2025, at 3:00 p.m. GMT (10:00 a.m. ET)

8th Annual Evercore Healthcare Conference
Presenting on Tuesday, December 2, 2025, at 10:50 a.m. ET

Piper Sandler 37th Annual Healthcare Conference
Wednesday, December 3, 2025

Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be available for up to 30 days following each event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Chimerix

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page